RegeneRx Biopharmaceuticals Inc. announced that the company has retained Alan Klein, MBA, on a part-time basis as Chief Business Officer (CBO) primarily responsible for product licensing, in particular RGN-352, as well as financing initiatives, commercialization modeling, grant applications, and intellectual property development. Mr. Klein previously held senior positions at public and private companies, including Quintiles International, Gene Logic, and Sequella Inc. He has been responsible for generating numerous out-licensing, in-licensing, and M&A transactions, valued at over $1 billion in aggregate, with major biotech and pharmaceutical companies throughout the world. On October 31, 2014, Dane Saglio submitted his resignation as Chief Financial Officer of the company.

Mr. Saglio will perform the duties of principal financial officer of the company until the filing of the company's Quarterly Report on Form 10-Q for the third fiscal quarter of 2014. Mr. Saglio will remain as a consultant to the company after the filing date.